Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin Therapy for Depression in Parkinson's Disease
NCT06455293Phase 2Recruiting
- Start
- Aug 2024
- Primary completion
- Jun 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in major depressive disorder (MDD). Started Aug 2024; status: recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06455293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06455293.